![](https://thenewyorkentrepreneur.com/wp-content/uploads/2024/07/107198777-16771566112023-01-20t224759z_376389922_rc2a2w9juz4s_rtrmadp_0_eisai-biogen-alzheimers-fda-cNdfKc-scaled.jpeg)
European drug regulator rejects Alzheimer’s treatment Leqembi from Biogen, Eisai
Read Time:6 Second
The committee said Leqembi’s effect on delaying cognitive decline does not outweigh “the risk of serious side effects associated with the medicine.”